Subscribe to Updates in Healthcare

RSS By Email

RSS By RSS

Add to Google Reader or Homepage

Subscribe in Bloglines


The Expertise Imperative and Compliance Technology
Access to a diverse array of specialized expert inputs drives superior decisions in every organizational context: within corporations, by investors and consultancies, and within nonprofits. When decision makers are confident of their decision inputs, they can respond more quickly and creatively to challenges and opportunities.Learn more about GLG's Compliance Framework


This page may include content provided by Council Members, your access to which is subject to the Terms of Use.
Find Out More

All GLG News Analyses Filed Under: Oncology

Articles with lock require a GLG News subscription
Posted February 21, 2008
Avastin (Genentech): Approval in breast cancer? It would be the correct thing to do!
Analysis of: Genentech has billions at stake in FDA battle | sanfrancisco.bizjournals.com
Author: GLG Member Program Contributor
Genentech has it's fingers crossed Re: approval or rejection of Avastin in breast cancer. If rejected it will lose it's compendia listing also adversely effecting insurance reimbursement.
Posted February 21, 2008
More than just AVASTIN
Analysis of: Genentech has billions at stake in FDA battle | sanfrancisco.bizjournals.com
Author: GLG Member Program Contributor
Genentech will have more battles to fight in the future aside from Avastin.  This medication appears extremely promising for the treatment of breast cancer, however, physicians are still mixed in their opinions about its place in the treatment of breast cancer.
Posted February 20, 2008
Picoplatin (Poniard) in Metastatic Prostate Cancer: Why not?
Analysis of: Poniard Pharmaceuticals Announces Positive First-line Phase 1 Safety and Efficacy Data With Picoplatin in Metastatic Prostate Cancer Patients | www.pipelinereview.com
Author: GLG Member Program Contributor
Picoplatin + Taxotere (Sanofi) appears in a Phase I trial, to be better than Taxotere alone in reducing PSA levels in metastatic prostate cancer (MPCA.)      (Comparing historical, not head to head data)
Posted February 20, 2008
GVAX (Cell Genesys) In Metastatic Prostate Carcinoma (MPCA). I'm Impressed So Far!
Analysis of: Cell Genesys Reports Association Between Immune Response and Patient Survival in Phase 2 Trial of GVAX Immunotherapy for Prostate Cancer | www.pipelinereview.com
Author: GLG Member Program Contributor
Immunologic response translated into improved survivals in 1/2 of the trial subjects!
Eric Whitman Posted February 20, 2008
More misleading Provenge data from Dendreon
Analysis of: Dendreon Presents Data Correlating the Cumulative Potency of PROVENGE(R) to Overall Survival | www.pipelinereview.com
Author: Eric Whitman, Medical Director, Office of Grants and Research Atlantic Health System Inc
This data attempts, yet again, to suggest that Provenge is more effective when the cell counts are higher, and more of the cells have CD54 "helper" antigens on their surface. These data are similar to other misleading news releases about Provenge from Dendreon. This is a subset of patients from...
Posted February 19, 2008
Good Step, but Still a lot of Details to Check
Analysis of: Dendreon Presents Data Correlating the Cumulative Potency of PROVENGE(R) to Overall Survival | www.pipelinereview.com
Author: GLG Member Program Contributor
It appears they finally made an attempt to infer causality from a previous result and determine what, if any, treatment effect was implied. I'm quite happy to see this type of analysis but would want to look at all the details, including the raw data if possible, before drawing too many...
Posted February 19, 2008
Novel molecules and diagnostic tests
Analysis of: Kidney Cancer Drug Linked to Higher Rate of Heart Problems | www.washingtonpost.com
Author: Joseph Schappert, Medical Director Icon Central Laboratories, Inc.
Diagnostic tools are availible to identify these adverse effects at an early stage in their clinical development. These tools should mitigate the seriousness of these adverse events.
Posted February 19, 2008
Need for cardiac evaluation in patients receiving novel cancer treatments
Analysis of: Kidney Cancer Drug Linked to Higher Rate of Heart Problems | www.washingtonpost.com
Author: GLG Member Program Contributor
Patients with rare malignancies, especially those with already metastatic diseases, are being treated with novel oncologic agents.  However, as is being seen with many drugs, the hemodynamic consequences of these agents, in many cases a rise in blood pressure, may lead to cardiovascular consequences. ...
Posted February 19, 2008
Cardiotoxicity associated with tyrosine kinase inhibitors
Analysis of: Kidney Cancer Drug Linked to Higher Rate of Heart Problems | www.washingtonpost.com
Author: GLG Member Program Contributor
undefined The cardiomyocyte is highly sensitive to perturbations in energy generation, largely because of its huge energy demani (Force, Nat Rev Cancer 2007). Mitochondrial dysfunction and energy depletion seem to be a common theme in cardiotoxicity. However, unlike in anthracycline cardiotoxicity,...
Posted February 19, 2008
Strike One for Sutent
Analysis of: Kidney Cancer Drug Linked to Higher Rate of Heart Problems | www.washingtonpost.com
Author: Michael Grossbard, Professor of Clinical Medicine Columbia University College of Physicians and Surgeons
Several agents have recently received FDA approval for the treatment of renal cell carcinoma including Sutent, Nexavar and Torisel.  The recent study describes a 15% rate of cardiovascular toxicities in patients  receiving Sutent including heart failure.  Y+This is a higher rate than...
Previous Page : 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 Next251 to 260 of 777

More GLG News in
Healthcare

Most Popular:
Source Article | Expert Analyses
 

GLG News: What Experts Think Is Important





Analytics


Generated at 2008-11-21T13:45:47.600